<DOC>
	<DOCNO>NCT00552461</DOCNO>
	<brief_summary>The purpose study determine whether use rituximab effective treating pulmonary alveolar proteinosis lead improvement lung function disease status .</brief_summary>
	<brief_title>Prospective Trial Rituximab Primary Pulmonary Alveolar Proteinosis</brief_title>
	<detailed_description>The goal study conduct prospective , open-label 6-month trial rituximab patient present symptomatic primary idiopathic PAP . A total 10 subject primary PAP enrol 12 month East Carolina University . Patients age 18 clinical diagnosis moderate symptomatic idiopathic PAP , establish appropriate clinical history , radiographic physiologic finding , presence circulate anti-GM-CSF antibody , confirmatory finding bronchoscopy bronchoalveolar lavage and/or open-lung biopsy recruit . Patients newly diagnose PAP establish disease may consider study .</detailed_description>
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis primary PAP ( new chronic ) presence antiGMCSF antibody Moderately symptomatic disease PaO2 &lt; 70 room air le 6 L/min oxygen Able give write informed consent comply requirement study Adequate renal liver function Negative serum pregnancy test ( woman child bear age ) acceptable birth control study completion Severe PAP require inpatient care urgent therapy bilateral whole lung lavage Treatment investigational agent within 4 week screen History severe allergic anaphylactic reaction humanize murine monoclonal antibody History HIV , recurrent significant infection recurrent bacterial infection Known active bacterial , viral , fungal , mycobacterial , infection Ongoing use high dose steroid ( &gt; 10mg/day ) unstable steroid dose Significant cardiac pulmonary disease blood disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Pulmonary alveolar proteinosis</keyword>
	<keyword>Primary Pulmonary alveolar proteinosis</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Idiopathic</keyword>
	<keyword>Symptomatic</keyword>
	<keyword>GM-CSF Antibody</keyword>
</DOC>